Explicit|23|41|134..136|0,1,1,1,1,1,1,5,0|as|||as|||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||9..132|0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2|Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter|Inh|Null|Null|Null||||137..211|0,1,1,1,1,1,1,5,1|companies with newer, big-selling prescription drugs fared especially well|Inh|Null|Null|Null|||||||||
Explicit|23|41|250..257|1,2|however|||however|||Comparison.Contrast||||Wr|Comm|Null|Null||||9..132|0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2|Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter|Inh|Null|Null|Null||||215..248;259..385|1,0;1,1;1,3;1,4;1,5;1,6|For the third consecutive quarter most of the companies' revenues were battered by adverse foreign-currency translations as a result of the strong dollar abroad|Inh|Null|Null|Null|||||||||
Implicit|23|41||||620|3||while||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||403..618|2,1,1|that Merck & Co., Eli Lilly & Co., Warner-Lambert Co. and the Squibb Corp. unit of Bristol-Myers Squibb Co. all benefited from strong sales of relatively new, higher-priced medicines that provide wide profit margins|Ot|Comm|Null|Null|389..402|2,0;2,1,0;2,2|Analysts said|620..803|3|Less robust earnings at Pfizer Inc. and Upjohn Co. were attributed to those companies' older products, many of which face stiffening competition from generic drugs and other medicines|Inh|Null|Null|Null|||||||||
Explicit|23|41|1057..1068|5,0,0|As a result|||as a result|||Contingency.Cause.Result||||Ot|Comm|Null|Null|1166..1183|5,1;5,2;5,3;5,4;5,5|Mr. Riccardo said|866..985|4,1,1,0;4,1,1,1,0;4,1,1,1,1;4,1,1,1,2,0;4,1,1,1,2,1,0;4,1,1,1,2,1,1;4,1,1,1,2,1,2,0;4,1,1,1,2,1,2,1,0;4,1,1,1,2,1,2,1,1|that over the past few years most drug makers have shed their slow-growing businesses and instituted other cost savings|Ot|Comm|Null|Null|807..865|4,0;4,1,0;4,2|Joseph Riccardo, an analyst with Bear, Stearns & Co., said|1071..1163|5,0,1;5,0,2;5,0,3;5,0,4|major new products are having significant impact, even on a company with very large revenues|Inh|Null|Null|Null||||987..1055|4,1,1,1,2,1,2,1,2|such as consolidating manufacturing plants and administrative staffs|||
Implicit|23|41||||1307|7||in fact||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||1201..1305|6,1,1|profit for the dozen or so big drug makers, as a group, is estimated to have climbed between 11% and 14%|Ot|Comm|Null|Null|1187..1200|6,0;6,1,0;6,2|Analysts said|1307..1335;1388..1499|7,0;7,3,1|While that's not spectacular that the rate of growth will "look especially good as compared to other companies if the economy turns downward|Ot|Comm|Null|Null|1337..1387|7,1;7,2;7,3,0;7,4;7,5|Neil Sweig, an analyst with Prudential Bache, said||||||
Explicit|23|41|1307..1312|7,0,0|While|||while|||Comparison.Contrast||||Wr|Comm|Null|Null||||1388..1499|7,3,1|that the rate of growth will "look especially good as compared to other companies if the economy turns downward|Ot|Comm|Null|Null|1337..1387|7,1;7,2;7,3,0;7,4;7,5|Neil Sweig, an analyst with Prudential Bache, said|1313..1335|7,0,1|that's not spectacular|Inh|Null|Null|Null|||||||||
Explicit|23|41|1470..1472|7,3,1,1,1,2,2,0|if|||if|||Contingency.Condition.Hypothetical||||Ot|Comm|Null|Null|1337..1387|7,1;7,2;7,3,0;7,4;7,5|Neil Sweig, an analyst with Prudential Bache, said|1388..1469|7,3,1,0;7,3,1,1,0;7,3,1,1,1,0;7,3,1,1,1,1;7,3,1,1,1,2,0;7,3,1,1,1,2,1|that the rate of growth will "look especially good as compared to other companies|Inh|Null|Null|Null||||1473..1499|7,3,1,1,1,2,2,1|the economy turns downward|Inh|Null|Null|Null|||||||||
Implicit|23|41||||1799|9||in fact||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||1524..1647|8,1,1,0;8,1,1,1,0;8,1,1,1,1,0;8,1,1,1,1,1;8,1,1,1,1,2;8,1,1,1,1,3,0;8,1,1,1,1,3,1,0;8,1,1,1,1,3,1,1;8,1,1,1,1,3,1,2,0;8,1,1,1,1,3,1,2,1,0;8,1,1,1,1,3,1,2,1,1,0;8,1,1,1,1,3,1,2,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,1,1|that Merck's profit for the quarter rose by about 22%, propelled by sales of its line-up of fast-growing prescription drugs|Ot|Comm|Null|Null|1504..1523|8,0;8,1,0;8,2|Mr. Sweig estimated|1799..1921|9,0|Profit climbed even though Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar|Ot|Comm|Null|Null|1923..1937|9,1;9,2;9,3;9,4|Mr. Sweig said||||||
Explicit|23|41|1814..1825|9,0,1,1,0;9,0,1,1,1|even though|||though|||Comparison.Concession.Expectation||||Ot|Comm|Null|Null|1923..1937|9,1;9,2;9,3;9,4|Mr. Sweig said|1799..1813|9,0,0;9,0,1,0|Profit climbed|Inh|Null|Null|Null||||1826..1921|9,0,1,1,2|Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar|Inh|Null|Null|Null|||||||||
Implicit|23|41||||1939|10||in fact||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||1799..1921|9,0|Profit climbed even though Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar|Ot|Comm|Null|Null|1923..1937|9,1;9,2;9,3;9,4|Mr. Sweig said|1939..2017|10|In the third quarter of 1988, Merck earned $311.8 million, or 79 cents a share|Inh|Null|Null|Null|||||||||
Implicit|23|41||||2264|13||in fact||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||2138..2262|12,1,1,1,1,1|that Lilly's earnings for the quarter jumped about 20%, largely because of the performance of its new anti-depressant Prozac|Ot|PAtt|Null|Null|2125..2137|12,1,1,0;12,1,1,1,0;12,1,1,1,1,0|he estimated|2264..2357|13|The drug, introduced last year, is expected to generate sales of about $300 million this year|Inh|Null|Null|Null|||||||||
Implicit|23|41||||2360|14||in other words||Expansion.Restatement.Generalization||||Wr|Comm|Null|Null||||2264..2357|13|The drug, introduced last year, is expected to generate sales of about $300 million this year|Inh|Null|Null|Null||||2360..2401|14,1|It's turning out to be a real blockbuster|Ot|Comm|Null|Null|2404..2418|14,0;14,2;14,3;14,4;14,5;14,6|Mr. Sweig said||||||
EntRel|23|41||||2499|16|||||||||||||||2422..2497|15|In last year's third quarter, Lilly earned $171.4 million, or $1.20 a share||||||||2499..2538|16|In Indianapolis, Lilly declined comment|||||||||||||
Explicit|23|41|2602..2606|17,1,1,1,1,1,1|also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||2125..2262|12,1,1|he estimated that Lilly's earnings for the quarter jumped about 20%, largely because of the performance of its new anti-depressant Prozac|Ot|Comm|Null|Null|2110..2124|12,0;12,1,0;12,2|Mr. Sweig said|2564..2601;2607..2714|17,1,1,0;17,1,1,1,0;17,1,1,1,1,0;17,1,1,1,1,1,0;17,1,1,1,1,1,2|they expected Warner-Lambert's profit to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year|Ot|Comm|Null|Null|2542..2563|17,0;17,1,0;17,2|Several analysts said||||||
EntRel|23|41||||2716|18|||||||||||||||2542..2714|17|Several analysts said they expected Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year||||||||2716..2853|18|The company is praised by analysts for sharply lowering its costs in recent years and shedding numerous companies with low profit margins|||||||||||||
Implicit|23|41||||2855|19||because||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||2716..2853|18|The company is praised by analysts for sharply lowering its costs in recent years and shedding numerous companies with low profit margins|Inh|Null|Null|Null||||2855..2883;2900..2985|19,0;19,2;19,3|The company's lean operation allowed sharp-rising sales from its cholesterol drug, Lopid, to power earnings growth|Ot|Comm|Null|Null|2885..2898|19,1|analysts said||||||
Implicit|23|41||||2987|20||as||Contingency.Cause.Reason||||Wr|Comm|Null|Null||||2855..2883;2900..2985|19,0;19,2;19,3|The company's lean operation allowed sharp-rising sales from its cholesterol drug, Lopid, to power earnings growth|Ot|Comm|Null|Null|2885..2898|19,1|analysts said|2987..3076|20|Lopid sales are expected to be about $300 million this year, up from $190 million in 1988|Inh|Null|Null|Null|||||||||
Implicit|23|41||||3078|21||indeed||Expansion.Conjunction||||Wr|Comm|Null|Null||||2987..3076|20|Lopid sales are expected to be about $300 million this year, up from $190 million in 1988|Inh|Null|Null|Null||||3078..3181|21|In Morris Plains, N.J., a spokesman for the company said the analysts' projections are "in the ballpark|Inh|Null|Null|Null|||||||||
EntRel|23|41||||3443|23|||||||||||||||3186..3441|22|Squibb's profit, estimated by analysts to be about 18% above the $123 million, or $1.25 a share, it earned in the third quarter of 1988, was the result of especially strong sales of its Capoten drug for treating high blood pressure and other heart disease||||||||3443..3518|23|The company was officially merged with Bristol-Myers Co. earlier this month|||||||||||||
EntRel|23|41||||3520|24|||||||||||||||3443..3518|23|The company was officially merged with Bristol-Myers Co. earlier this month||||||||3520..3553|24|Bristol-Myers declined to comment|||||||||||||
Explicit|23|41|3726..3741|25,1,1,1,1,1,0;25,1,1,1,1,1,1|largely because|||because|||Contingency.Cause.Reason||||Ot|Comm|Null|Null|3557..3590|25,0;25,1,0;25,2;25,3|Mr. Riccardo of Bear Stearns said|3591..3725|25,1,1,0;25,1,1,1,0;25,1,1,1,1,0|that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are|Inh|Null|Null|Null||||3743..3782|25,1,1,1,1,1,3|those companies are really managed well|Inh|Null|Null|Null|||||||||
EntRel|23|41||||3785|26|||||||||||||||3557..3782|25|Mr. Riccardo of Bear Stearns said that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are largely because "those companies are really managed well||||||||3785..3940|26|ScheringPlough earned $94.4 million, or 84 cents a share, while Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier|||||||||||||
Explicit|23|41|3843..3848|26,1,3,0|while|||while|||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||3785..3841|26,0;26,1,0;26,1,1;26,1,2;26,2|ScheringPlough earned $94.4 million, or 84 cents a share|Inh|Null|Null|Null||||3849..3940|26,1,3,1|Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier|Inh|Null|Null|Null|||||||||
Implicit|23|41||||4133|28||also||Expansion.Conjunction||||Wr|Comm|Null|Null||||3999..4131|27,3,1|the company has "no problems" with the average estimate by a analysts that third-quarter earnings per share rose by about 19%, to $1|Ot|Comm|Null|Null|3944..3998|27,0;27,1;27,2;27,3,0;27,4|In Madison, N.J., a spokesman for Schering-Plough said|4133..4212|28,0,0;28,0,1,0;28,0,1,1,0;28,0,1,1,1,0;28,0,1,1,1,1,0;28,0,1,1,1,1,1;28,0,1,1,1,1,2|The company expects to achieve the 20% increase in full-year earnings per share|Ot|Comm|Null|Null|4245..4263|28,1;28,2;28,3;28,4|the spokesman said||||||
Explicit|23|41|4267..4276|29,0|Meanwhile|||meanwhile|||Comparison.Contrast.Juxtaposition||||Wr|Comm|Null|Null||||1524..1577;2138..2192;2578..2714;3225..3321;3591..3721;3661..3721|8,1,1,0;8,1,1,1,0;8,1,1,1,1,0;8,1,1,1,1,1;8,1,1,1,1,2;12,1,1,1,1,1,0;12,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,1;12,1,1,1,1,1,1,1,2;17,1,1,1,1,1;22,2,1,2;25,1,1,0;25,1,1,1,0;25,1,1,1,0,2;25,1,1,1,0,3|that Merck's profit for the quarter rose by about 22% that Lilly's earnings for the quarter jumped about 20% Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year to be about 18% above the $123 million, or $1.25 a share, it earned in the third quarter of 1988 that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% , and Bristol-Meyers's expected profit increase of about 13%|Ot|Ctrl|Null|Null|3203..3224;3557..3590|22,2,0;22,2,1,0;22,2,1,1;25,0;25,1,0;25,2;25,3|estimated by analysts Mr. Riccardo of Bear Stearns said|4404..4426|29,3,1,1,1,2,1,1,1,1|to decline by about 5%|Ot|Ctrl|Null|Null|4366..4403|29,3,1,1,1,2,1,0;29,3,1,1,1,2,1,1,0;29,3,1,1,1,2,1,1,1,0|earnings in the quarter were expected||||||
Explicit|23|41|4363..4365|29,3,1,1,1,2,0|as|||as|||Contingency.Pragmatic cause.Justification||||Ot|Comm|Null|Null|4278..4291|29,1;29,2;29,3,0;29,4|analysts said|4267..4276;4292..4361|29,0;29,1;29,3,1,0;29,3,1,1,0;29,3,1,1,1,0;29,3,1,1,1,1;29,4|Meanwhile Pfizer's recent string of lackluster quarterly performances continued|Inh|Null|Null|Null||||4366..4426|29,3,1,1,1,2,1|earnings in the quarter were expected to decline by about 5%|Inh|Null|Null|Null|||||||||
Implicit|23|41||||4428|30||in particular||Expansion.Restatement.Specification||||Wr|Comm|Null|Null||||4292..4426|29,3,1|Pfizer's recent string of lackluster quarterly performances continued, as earnings in the quarter were expected to decline by about 5%|Ot|Comm|Null|Null|4278..4291|29,1;29,2;29,3,0;29,4|analysts said|4428..4572|30|Sales of Pfizer's important drugs, Feldene for treating arthritis, and Procardia, a heart medicine, have shrunk because of increased competition|Inh|Null|Null|Null|||||||||
AltLex|23|41|4614..4617|31,1,1,4|too||||||Expansion.Conjunction||||Wr|Comm|Null|Null||||4428..4572|30|Sales of Pfizer's important drugs, Feldene for treating arthritis, and Procardia, a heart medicine, have shrunk because of increased competition|Inh|Null|Null|Null||||4575..4617|31,1|The (strong) dollar hurt Pfizer a lot, too|Ot|Comm|Null|Null|4620..4634|31,0;31,2;31,3;31,4;31,5;31,6|Mr. Sweig said||||||
EntRel|23|41||||4636|32|||||||||||||||4575..4634|31|The (strong) dollar hurt Pfizer a lot, too," Mr. Sweig said||||||||4636..4714|32|In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share|||||||||||||
EntRel|23|41||||4716|33|||||||||||||||4636..4714|32|In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share||||||||4716..4757|33|In New York, the company declined comment|||||||||||||
EntRel|23|41||||4922|35|||||||||||||||4761..4920|34|Analysts said they expected Upjohn's profit to be flat or rise by only about 2% to 4% as compared with $89.6 million, or 49 cents a share, it earned a year ago||||||||4922..5003|35|Upjohn's biggest-selling drugs are Xanax, a tranquilizer, and Halcion, a sedative|||||||||||||
Explicit|23|41|5185..5189|37,0,0|Also|||also|||Expansion.Conjunction||||Wr|Comm|Null|Null||||5007..5183|36|Sales of both drugs have been hurt by new state laws restricting the prescriptions of certain tranquilizing medicines and adverse publicity about the excessive use of the drugs|Inh|Null|Null|Null||||5191..5412|37,0,1;37,0,2;37,0,3;37,0,4;37,0,5|the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year, but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising|Ot|Comm|Null|Null|5414..5427|37,1;37,2;37,3;37,4|analysts said||||||
Explicit|23|41|5288..5291|37,0,4|but|||but|||Comparison.Contrast||||Ot|Comm|Null|Null|5414..5427|37,1;37,2;37,3;37,4|analysts said|5185..5286|37,0,0;37,0,1;37,0,2;37,0,3|Also, the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year|Inh|Null|Null|Null||||5292..5412|37,0,5|the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising|Inh|Null|Null|Null|||||||||
EntRel|23|41||||5429|38|||||||||||||||5185..5427|37|Also, the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year, but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising, analysts said||||||||5429..5473|38|In Kalamazoo, Mich., Upjohn declined comment|||||||||||||
